These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 9645167)

  • 21. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin's lymphoma.
    Manohar K; Mittal BR; Bhattacharya A; Malhotra P; Varma S
    Nucl Med Commun; 2012 Sep; 33(9):974-81. PubMed ID: 22811258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma.
    Dittmann H; Sokler M; Kollmannsberger C; Dohmen BM; Baumann C; Kopp A; Bares R; Claussen CD; Kanz L; Bokemeyer C
    Oncol Rep; 2001; 8(6):1393-9. PubMed ID: 11605073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission.
    Truong Q; Shah N; Knestrick M; Curley B; Hu Y; Craig M; Hamadani M
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):50-5. PubMed ID: 24119465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucosa-associated lymphoid tissue lymphoma studied with FDG-PET: a comparison with CT and endoscopic findings.
    Enomoto K; Hamada K; Inohara H; Higuchi I; Tomita Y; Kubo T; Hatazawa J
    Ann Nucl Med; 2008 May; 22(4):261-7. PubMed ID: 18535876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma.
    Crocchiolo R; Fallanca F; Giovacchini G; Ferreri AJ; Assanelli A; Verona C; Pescarollo A; Bregni M; Ponzoni M; Gianolli L; Fazio F; Ciceri F
    Ann Hematol; 2009 Dec; 88(12):1229-36. PubMed ID: 19468730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation.
    Park YJ; Hyun SH; Moon SH; Lee KH; Min BH; Lee JH; Kim WS; Kim SJ; Choi JY
    Sci Rep; 2021 Apr; 11(1):9243. PubMed ID: 33927319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour inhomogeneities on magnetic resonance imaging, a new factor with prognostic information in non-Hodgkin's lymphomas.
    Rehn SM; Rodriguez M; Bergström SR; Nyman RS; Glimelius BL
    Leuk Lymphoma; 1997 Feb; 24(5-6):501-11. PubMed ID: 9086440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [18FDG PET in the management of malignant lymphoma].
    Cui RX; Zhou Q
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Dec; 25(6):645-9. PubMed ID: 14714303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.
    Rigacci L; Castagnoli A; Dini C; Carpaneto A; Matteini M; Alterini R; Carrai V; Nassi L; Bernardi F; Pieroni C; Bosi A
    Oncol Rep; 2005 Nov; 14(5):1209-14. PubMed ID: 16211287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. Accuracy in a multicenter series of 372 patients.
    Chen-Liang TH; Martin-Santos T; Jerez A; Senent L; Orero MT; Remigia MJ; Muiña B; Romera M; Fernandez-Muñoz H; Raya JM; Fernandez-Gonzalez M; Lancharro A; Villegas C; Carlos Herrera J; Frutos L; Luis Navarro J; Uña J; Igua C; Sanchez-Vaño R; Cozar Mdel P; Contreras J; Sanchez-Blanco JJ; Perez-Ceballos E; Ortuño FJ
    Am J Hematol; 2015 Aug; 90(8):686-90. PubMed ID: 25925613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
    Maisey NR; Hill ME; Webb A; Cunningham D; Flux GD; Padhani A; Ott RJ; Norman A; Bishop L
    Eur J Cancer; 2000 Jan; 36(2):200-6. PubMed ID: 10741278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Sequential analysis of the integrated images of PET, CT and MR in malignant brain tumors before and after radiotherapy].
    Suzuki A; Mineura K; Sasajima T; Kowada M; Ogawa T; Hatazawa J; Uemura K
    No To Shinkei; 1996 May; 48(5):449-57. PubMed ID: 8672304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients.
    Van Den Bossche B; Lambert B; De Winter F; Kolindou A; Dierckx RA; Noens L; Van De Wiele C
    Nucl Med Commun; 2002 Nov; 23(11):1079-83. PubMed ID: 12411836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography.
    Stumpe KD; Urbinelli M; Steinert HC; Glanzmann C; Buck A; von Schulthess GK
    Eur J Nucl Med; 1998 Jul; 25(7):721-8. PubMed ID: 9662594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
    Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
    Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-Hodgkin lymphoma: predicting prognostic grade with MR imaging.
    Rehn SM; Nyman RS; Glimelius BL; Hagberg HE; Sundström JC
    Radiology; 1990 Jul; 176(1):249-53. PubMed ID: 2353098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Value of endosonography in diagnostic staging of primary gastric lymphoma (MALT type)].
    Hoepffner N; Lahme T; Gilly J; Menzel J; Koch P; Foerster EC
    Med Klin (Munich); 2003 Jun; 98(6):313-7. PubMed ID: 12811415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
    Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.